DE1213032T1 - Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür - Google Patents

Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür

Info

Publication number
DE1213032T1
DE1213032T1 DE1213032T DE02075756T DE1213032T1 DE 1213032 T1 DE1213032 T1 DE 1213032T1 DE 1213032 T DE1213032 T DE 1213032T DE 02075756 T DE02075756 T DE 02075756T DE 1213032 T1 DE1213032 T1 DE 1213032T1
Authority
DE
Germany
Prior art keywords
cells
site
specific
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1213032T
Other languages
English (en)
Inventor
Elizabeth G Nabel
Gary J Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE1213032(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Michigan filed Critical University of Michigan
Publication of DE1213032T1 publication Critical patent/DE1213032T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22084—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance stone- or thrombus-dissolving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
DE1213032T 1991-06-28 1992-06-26 Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür Pending DE1213032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72450991A 1991-06-28 1991-06-28
US07/741,244 US5328470A (en) 1989-03-31 1991-07-26 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor

Publications (1)

Publication Number Publication Date
DE1213032T1 true DE1213032T1 (de) 2003-02-06

Family

ID=27110984

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232497T Expired - Fee Related DE69232497T2 (de) 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
DE1213032T Pending DE1213032T1 (de) 1991-06-28 1992-06-26 Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69232497T Expired - Fee Related DE69232497T2 (de) 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür

Country Status (9)

Country Link
US (1) US5328470A (de)
EP (4) EP1213032B1 (de)
JP (3) JP3712409B2 (de)
AT (2) ATE214576T1 (de)
CA (1) CA2112376A1 (de)
DE (2) DE69232497T2 (de)
DK (1) DK0591385T3 (de)
ES (1) ES2301602T3 (de)
WO (1) WO1993000051A1 (de)

Families Citing this family (577)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US6743623B2 (en) * 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5586982A (en) * 1992-04-10 1996-12-24 Abela; George S. Cell transfection apparatus and method
US5713848A (en) 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US6936025B1 (en) 1992-05-19 2005-08-30 Bacchus Vascular, Inc. Thrombolysis device
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
EP0746625B1 (de) 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
DE69333886T2 (de) * 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
PT698109E (pt) * 1993-05-10 2002-12-31 Univ Michigan Transferencia de genes para dentro de celulas epiteliais pancreaticas
AU7019494A (en) * 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
EP1624068A1 (de) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
ES2077519B1 (es) * 1993-11-22 1996-07-01 Fernandez De Lomana Euge Anaya Cateter intraaortico para perfusion y conservacion renal.
US5792106A (en) * 1993-12-02 1998-08-11 Scimed Life Systems, Inc. In situ stent forming catheter
US5409012A (en) * 1993-12-30 1995-04-25 Boston Scientific Corporation Sample collection using catheter with expandable member
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
WO1995027494A1 (en) * 1994-04-11 1995-10-19 Sloan-Kettering Institute For Cancer Research DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US5713861A (en) * 1994-10-17 1998-02-03 Vanarthos; William Trauma urethral catheter and method of using same
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5888821A (en) * 1994-12-28 1999-03-30 Max-Delbruck-Centrum Fur Molekulare Medizin Cholesterol derivative for liposomal gene transfer
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU4740096A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Direct administration of gene delivery vehicles at multiple sites
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6210356B1 (en) 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US5837693A (en) * 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6531455B1 (en) * 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei
US5922687A (en) * 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6322548B1 (en) 1995-05-10 2001-11-27 Eclipse Surgical Technologies Delivery catheter system for heart chamber
ATE226094T1 (de) * 1995-05-16 2002-11-15 Karl Tryggvason Verfahren zur arzneistoffabgabe mittels gentherapie
US6638264B1 (en) * 1995-05-16 2003-10-28 Biostratum Incorporation Perfusion apparatus and methods for pharmaceutical delivery
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5674198A (en) * 1995-06-23 1997-10-07 Cordis Corporation Tandem balloon catheter
RU2187301C2 (ru) * 1995-06-27 2002-08-20 Бавариан Нордик А/С Капсула для клеток, продуцирующих вирусные частицы, способ ее получения и использования
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5725568A (en) * 1995-06-27 1998-03-10 Scimed Life Systems, Inc. Method and device for recanalizing and grafting arteries
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
HUP9902068A3 (en) * 1995-11-30 2001-02-28 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5998384A (en) * 1996-01-26 1999-12-07 Hisamitsu Pharmaceutical Co., Inc. Endoscopic administration of an HSV-tk gene to treat digestive organ cancer
ATE333892T1 (de) * 1996-02-09 2006-08-15 Pi-Wan Cheng Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
US6321109B2 (en) 1996-02-15 2001-11-20 Biosense, Inc. Catheter based surgery
US6037332A (en) * 1996-02-20 2000-03-14 Emory University Method of urinary bladder instillation
US5866340A (en) * 1996-03-22 1999-02-02 Johns Hopkins University Selective expression of desired genes in cells expressing oncoproteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
WO1998002040A1 (en) 1996-07-17 1998-01-22 Medtronic, Inc. System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
WO1998002150A1 (en) * 1996-07-17 1998-01-22 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
US6443974B1 (en) * 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6494861B1 (en) 1997-01-15 2002-12-17 Boston Scientific Corporation Drug delivery system
US5868719A (en) * 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
WO1998033545A1 (en) * 1997-02-04 1998-08-06 Cook Urological Inc. Suprapubic drainage catheter
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
ES2303726T3 (es) 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
ES2285768T5 (es) 1997-04-16 2011-12-22 Millennium Pharmaceuticals, Inc. Proteínas crsp (proteínas segregadas ricas en cisteína), moléculas de ácido nucleico que codifican para las mismas y uso.
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) * 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6723063B1 (en) 1998-06-29 2004-04-20 Ekos Corporation Sheath for use with an ultrasound element
WO1998048711A1 (en) * 1997-05-01 1998-11-05 Ekos Corporation Ultrasound catheter
DE19726244C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
DE19729769A1 (de) 1997-07-11 1999-01-14 Cardiogene Gentherapeutische S Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
US6177272B1 (en) * 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
EP1024832A1 (de) * 1997-10-24 2000-08-09 Children's Medical Center Corporation Zelltransfektionvermehrungsförderende verfahrens für in vivo
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6197324B1 (en) 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6794369B2 (en) 1997-12-31 2004-09-21 Pharmasonics Methods, systems, and kits for intravascular nucleic acid delivery
AU2023199A (en) 1997-12-31 1999-07-19 Pharmasonics, Inc. Methods, systems, and kits for intravascular nucleic acid delivery
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
EP1053326A2 (de) 1998-02-06 2000-11-22 Collateral Therapeutics Varianten des angiogenen faktors vaskularer endothelialzell-wachstumsfaktor: vegf
US6148222A (en) * 1998-07-10 2000-11-14 Cardiocommand, Inc. Esophageal catheters and method of use
US7700353B2 (en) * 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
EP1736547A1 (de) * 1998-08-26 2006-12-27 Stürzl, Michael, Prof. Dr. rer. nat Guanylat-bindendes Protein (GBP-1) als Inhibitor der Endothelzell-Proliferation
US6312402B1 (en) 1998-09-24 2001-11-06 Ekos Corporation Ultrasound catheter for improving blood flow to the heart
US6689121B1 (en) 1998-09-24 2004-02-10 C. R. Bard, Inc. Systems and methods for treating ischemia
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
US6620139B1 (en) * 1998-12-14 2003-09-16 Tre Esse Progettazione Biomedica S.R.L. Catheter system for performing intramyocardiac therapeutic treatment
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US7122019B1 (en) 2000-11-28 2006-10-17 Flowmedica Inc. Intra-aortic renal drug delivery catheter
US7329236B2 (en) * 1999-01-11 2008-02-12 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6749598B1 (en) * 1999-01-11 2004-06-15 Flowmedica, Inc. Apparatus and methods for treating congestive heart disease
US7780628B1 (en) 1999-01-11 2010-08-24 Angiodynamics, Inc. Apparatus and methods for treating congestive heart disease
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
JP2002538167A (ja) * 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
EP2368575B1 (de) * 1999-04-08 2014-10-01 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US6224566B1 (en) 1999-05-04 2001-05-01 Cardiodyne, Inc. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
US6565528B1 (en) 1999-05-07 2003-05-20 Scimed Life Systems, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US6641553B1 (en) * 1999-06-02 2003-11-04 Boston Scientific Corporation Devices and methods for delivering a drug
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7001766B2 (en) * 1999-07-20 2006-02-21 Curagen Corporation Nucleic acid sequences encoding human angiopoietin-like polypeptides
US6475744B1 (en) 1999-07-22 2002-11-05 The General Hospital Corporation Methods for identifying compounds which modulate circadian rhythm
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
AU782714B2 (en) * 1999-09-09 2005-08-25 Regents Of The University Of California, The Cationic liposome delivery of taxanes to angiogenic blood vessels
ATE361095T1 (de) * 1999-09-24 2007-05-15 Proteon Therapeutics Inc Verwendung von elastase zur öffnung verstopfter arterien und venen
US6855806B1 (en) * 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
US8808272B2 (en) * 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) * 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
PL208368B1 (pl) 2000-02-29 2011-04-29 Alcon Inc Sposób diagnozowania jaskry
EP1254230A2 (de) 2000-02-29 2002-11-06 Millennium Pharmaceuticals, Inc. 1983, 52881, 2398, 45449, 50289, and 52872, g-protein-gekoppelte rezeptoren und deren anwendungen
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
DE60125148T2 (de) * 2000-03-03 2007-09-27 Curagen Corp., New Haven Fctrx genannte proteine und dafür kodierende nuklein säure
US7517352B2 (en) 2000-04-07 2009-04-14 Bacchus Vascular, Inc. Devices for percutaneous remote endarterectomy
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
AU5716901A (en) 2000-04-21 2001-11-07 New England Medical Ct G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030219786A1 (en) * 2000-08-11 2003-11-27 Applied Research Systems Ars Holding N.V. Novel glycoproteins and methods of use thereof
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20040034193A1 (en) * 2001-06-13 2004-02-19 Samy Ashkar Biosynthetic oncolytic molecules and uses therefor
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2004505620A (ja) * 2000-08-03 2004-02-26 ザ　ユニバーシティ　オブ　ユタ　リサーチ　ファウンデーション 動静脈特性の操作
WO2002016644A1 (en) * 2000-08-18 2002-02-28 Massachusetts Institute Of Technology Inhibition of protein-protein interaction
US7651696B2 (en) * 2000-08-25 2010-01-26 Nexeon Medical Systems, Inc. Implantable device for treating disease states and methods of using same
US6740331B1 (en) 2000-08-25 2004-05-25 Global Gene Therapies, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
AU2001287000A1 (en) 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2001291087A1 (en) * 2000-09-20 2002-04-02 Amgen Inc. B7-like molecules and uses thereof
US7875585B2 (en) 2000-10-18 2011-01-25 Robert Sackstein Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide
EP2316976A1 (de) 2000-11-28 2011-05-04 Wyeth LLC Expressionsanalyse von FKBP Nukleinsäuren und Polypeptiden, die zur Diagnose und Behandlung von Prostatakrebs geeignet sind
US7037652B2 (en) 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20020177571A1 (en) * 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
US20050267061A1 (en) * 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7015012B2 (en) * 2001-02-09 2006-03-21 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
DE60227157D1 (de) 2001-02-13 2008-07-31 Us Gov Sec Army Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
BR0208637A (pt) 2001-04-02 2004-12-07 Wyeth Corp Pd-1, um receptor para b7-4, e usos dos mesmos
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
EP1572868A4 (de) 2001-04-16 2007-04-04 Wyeth Corp Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ATE347695T1 (de) 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
PL370139A1 (en) * 2001-06-07 2005-05-16 Wyeth A g-protein coupled receptor and uses therefor
EP1409737A4 (de) * 2001-06-15 2005-10-12 Interleukin Genetics Inc Verfahren zum nachweis und zur behandlung des frühen auftretens von mit dem altern zusammenhängenden beschwerden
US20040236377A1 (en) * 2001-07-02 2004-11-25 Medtronic, Inc. System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
CA2453183C (en) 2001-07-12 2016-05-10 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002323217B2 (en) 2001-08-15 2008-04-10 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US6808518B2 (en) * 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
JP2005534279A (ja) 2001-09-28 2005-11-17 ブリガム ヤング ユニバーシティ 新規なシクロオキシゲナーゼ変異体とその使用方法
SI1438065T1 (sl) * 2001-10-01 2013-03-29 Martizyme Pharma Corporation Uporaba kolagenaze za olajšanje prehoda vodilne žice skozi kronične arterijske okluzije
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US7745418B2 (en) * 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
AU2002359576A1 (en) 2001-12-03 2003-06-17 Ekos Corporation Catheter with multiple ultrasound radiating members
AU2002353016A1 (en) * 2001-12-03 2003-06-17 Ekos Corporation Small vessel ultrasound catheter
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
AU2002366803A1 (en) 2001-12-19 2003-07-09 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US6939374B2 (en) * 2001-12-21 2005-09-06 Scimed Life Systems, Inc. Stents, stenting systems, and related methods for agent delivery
NZ579419A (en) 2002-02-07 2011-02-25 Dyax Corp Albumin-fused kunitz domain peptides
US20040068189A1 (en) * 2002-02-28 2004-04-08 Wilson Richard R. Ultrasound catheter with embedded conductors
US7153685B2 (en) * 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20040009546A1 (en) * 2002-04-22 2004-01-15 Jan Holgersson Compositions and methods for inhibiting microbial adhesion
EP2392659B1 (de) 2002-06-17 2015-01-14 Thrasos Innovation, Inc. TDF-zugehörige Einzeldomänenverbindungen und Analoge davon
CA2491320A1 (en) * 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
EP2311978A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
US20050197624A1 (en) 2004-03-04 2005-09-08 Flowmedica, Inc. Sheath for use in peripheral interventions
EP1624909A2 (de) * 2002-09-20 2006-02-15 FlowMedica, Inc. Gerät und verfahren zur einführung eines intraaortakalen katheters durch eine ablageschleuse
JP2006508776A (ja) 2002-09-20 2006-03-16 フローメディカ，インコーポレイテッド 腎臓内カテーテルを介する選択的物質送達のための方法および装置
US7063679B2 (en) 2002-09-20 2006-06-20 Flowmedica, Inc. Intra-aortic renal delivery catheter
US7993325B2 (en) 2002-09-20 2011-08-09 Angio Dynamics, Inc. Renal infusion systems and methods
AU2003294226A1 (en) * 2002-09-20 2004-04-23 Flowmedica, Inc. Method and apparatus for intra aortic substance delivery to a branch vessel
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004047757A2 (en) * 2002-11-21 2004-06-10 University Of Massachusets Diagnosing and treating hematopoietic cancers
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
US7771372B2 (en) 2003-01-03 2010-08-10 Ekos Corporation Ultrasonic catheter with axial energy field
JP2007525423A (ja) * 2003-02-20 2007-09-06 プロテオン セラピューティクス，インコーポレーテッド 生体導管の疾患を治療および予防するための方法
US20050233342A1 (en) * 2003-03-07 2005-10-20 Muthiah Manoharan Methods of preventing off-target gene silencing
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
EP1620544B1 (de) * 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. Modifizierte irna-agentien
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
ATE513471T1 (de) * 2003-04-21 2011-07-15 Epeius Biotechnologies Corp Verfahren und zusammensetzungen zur behandlung von erkrankungen
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
WO2004093656A2 (en) * 2003-04-22 2004-11-04 Ekos Corporation Ultrasound enhanced central venous catheter
EP1635736A2 (de) 2003-06-05 2006-03-22 FlowMedica, Inc. Systeme und verfahren zur durchführung von bilateralen interventionen oder diagnose in verzweigten körperlumen
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
US20060134287A1 (en) * 2003-08-20 2006-06-22 Vimini Robert J Packaging and cooking bag and method for packaging and preparing a meat product
CN1871351B (zh) 2003-08-25 2010-06-23 富诺齐梅生物技术股份有限公司 一种新的真菌蛋白及其编码核酸
US7291604B2 (en) 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
US8680063B2 (en) * 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
ES2485848T3 (es) * 2003-09-12 2014-08-14 University Of Massachusetts ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
US20050059999A1 (en) * 2003-09-15 2005-03-17 Mongeon Luc R. Delivering genetic material to a stimulation site
MXPA06003402A (es) 2003-10-07 2006-06-27 Millennium Pharm Inc Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20050125914A1 (en) * 2003-11-18 2005-06-16 Gerard Malle Hair shaping composition comprising at least one- non-hydroxide base
ES2390273T3 (es) 2003-11-21 2012-11-08 Silk Road Medical, Inc. Aparato para el tratamiento de una arteria carótida
CA2487107A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from skeletal muscle
CA2487098A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
CA2554370A1 (en) * 2004-01-26 2005-08-25 Brett Premack Compositions and methods of use of w-peptides
US20070087986A1 (en) * 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
AU2005206388A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
AU2005206389A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
WO2005087217A1 (en) * 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
ES2423060T3 (es) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
GB0406728D0 (en) * 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
ES2527528T3 (es) * 2004-04-08 2015-01-26 Sangamo Biosciences, Inc. Métodos y composiciones para modular la contractilidad cardiaca
JP2007537298A (ja) 2004-05-14 2007-12-20 フロウメディカ， インコーポレイテッド うっ血性心不全の処置およびｂｎｐ療法のための両側性局所腎臓送達
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
EP1753458A4 (de) * 2004-05-19 2009-07-22 Wyeth Corp Modulation der immunglobulinproduktion und atopische erkrankungen
WO2006007375A2 (en) * 2004-06-16 2006-01-19 The General Hospital Corporation Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
EP1773871B1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Mit tdf verwandte verbindungen und analoga davon
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US20060051338A1 (en) 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
JP2008512099A (ja) 2004-09-07 2008-04-24 テレソン インスティテュート フォー チャイルド ヘルス リサーチ アレルギー性疾患の処置または予防のための物質
US20060069323A1 (en) * 2004-09-24 2006-03-30 Flowmedica, Inc. Systems and methods for bi-lateral guidewire cannulation of branched body lumens
WO2006036916A2 (en) 2004-09-24 2006-04-06 Alnylam Pharmaceuticals, Inc. Rnai modulation of apob and uses thereof
AU2005323303A1 (en) 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Bcr-Abl fusion gene and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
BRPI0515819A (pt) * 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
US8168588B2 (en) 2005-01-25 2012-05-01 Five Prime Therapeutics, Inc. Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions
ES2409686T3 (es) 2005-01-25 2013-06-27 Prolexys Pharmaceuticals, Inc. Derivados de quinoxalina como agentes antitumorales
EP1861126A4 (de) * 2005-03-22 2009-11-18 Harvard College Behandlung von proteinabbaustörungen
NZ563263A (en) 2005-05-17 2010-04-30 Univ Connecticut Composition and methods for immunomodulation in an organism
WO2006135783A2 (en) * 2005-06-10 2006-12-21 Wisconsin Alumni Research Foundation Compositions and methods for modulating angiogenesis
WO2006138690A2 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
NZ565172A (en) 2005-07-19 2012-12-21 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
CA2607668A1 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
WO2007018318A1 (ja) * 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
WO2007022506A2 (en) * 2005-08-18 2007-02-22 University Of Massachusetts Methods and compositions for treating neurological disease
WO2007024589A2 (en) * 2005-08-24 2007-03-01 The Trustees Of Columbia University In The City Of New York Phagocyte enhancement therapy for atherosclerosis
US20070072247A1 (en) * 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) * 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
WO2007030820A2 (en) 2005-09-09 2007-03-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
AU2006297126A1 (en) 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Methods and compositions for modulating immune tolerance
US20070100323A1 (en) * 2005-10-31 2007-05-03 Ludwig Florian N Facilitation of endothelialization by in situ surface modification
US20070197460A1 (en) * 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
EP1942948A4 (de) * 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
US8172792B2 (en) 2005-12-27 2012-05-08 Tyco Healthcare Group Lp Embolic protection systems for bifurcated conduits
CA2635011A1 (en) 2006-01-26 2007-11-22 Recopharma Ab Use of sialylated fusion polypeptides for inhibition of oculotropic viruses
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
AU2007221470B2 (en) 2006-02-10 2013-02-14 The University Of Cincinnati Phosphatase inhibitor Protein-1 as a regulator of cardiac function
US8222423B2 (en) * 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US20090221072A1 (en) * 2006-02-15 2009-09-03 Chen Thomas T Compositions and methods for modulating cell differentiation
US20070225750A1 (en) * 2006-03-10 2007-09-27 Brooke Ren Embolic protection systems
NZ587704A (en) 2006-03-31 2012-04-27 Alnylam Pharmaceuticals Inc Use of dsRNA for inhibiting expression of Eg5 gene
EP2343551B1 (de) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ-Modulatoren
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
EP2021511A4 (de) 2006-05-03 2010-02-10 Geisinger Clinic Diagnose- und prognoseverfahren für nichtalkoholische steatohepatitis (nash)
JP5497431B2 (ja) * 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
EA015676B1 (ru) 2006-05-11 2011-10-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии гена pcsk9
WO2007137156A2 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
CA2653451C (en) * 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8383597B2 (en) * 2006-05-25 2013-02-26 Cornell Research Foundation, Inc. G proteins in tumor growth and angiogenesis
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US8153369B2 (en) 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
US7771401B2 (en) 2006-06-08 2010-08-10 Angiodynamics, Inc. Selective renal cannulation and infusion systems and methods
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
CN103275980B (zh) 2006-07-11 2015-09-09 罗格斯新泽西州立大学 抗体、融合蛋白以及组合物
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
WO2008028044A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
CA2680436A1 (en) 2006-09-14 2008-03-20 Institut Pasteur Methods of using sip-10 to assess hcv clearance and/or response to interferon therapy
KR101161923B1 (ko) 2006-10-03 2012-07-03 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Ａｔａｐ 펩티드, 상기 펩티드를 엔코딩하는 핵산 및 이들과 관련된 사용 방법
US8192363B2 (en) 2006-10-27 2012-06-05 Ekos Corporation Catheter with multiple ultrasound radiating members
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
AU2008211227B2 (en) 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
CA2679954A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
US20100184823A1 (en) 2007-07-05 2010-07-22 Mark Aron Labow dsRNA For Treating Viral Infection
ES2913223T3 (es) * 2007-07-18 2022-06-01 Silk Road Medical Inc Sistemas para establecer flujo sanguíneo arterial carotídeo retrógrado
US8858490B2 (en) 2007-07-18 2014-10-14 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EP2617828B1 (de) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
ES2821762T3 (es) * 2008-02-05 2021-04-27 Silk Road Medical Inc Sistema de catéter de intervención
WO2009099764A1 (en) * 2008-02-05 2009-08-13 Silk Road Medical, Inc. Interventional sheath with retention features
CN101977632A (zh) 2008-02-19 2011-02-16 塞拉东公司 用于增强病毒载体于心肌中的摄取的组合物
EP2712926A2 (de) * 2008-03-05 2014-04-02 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5- und des VEGF-Gens
JP5788312B2 (ja) 2008-04-11 2015-09-30 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
JP2011519912A (ja) * 2008-05-09 2011-07-14 リコファーマ アーベー 志賀毒素および志賀様毒素を阻害するための組成物および方法
EP3384919A1 (de) 2008-06-02 2018-10-10 Dana Farber Cancer Institute, Inc. Cs1-peptide
EP2313505A2 (de) * 2008-07-15 2011-04-27 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur expressionshemmung von tgf-beta-rezeptorgenen
JP5665740B2 (ja) * 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
US8574245B2 (en) 2008-08-13 2013-11-05 Silk Road Medical, Inc. Suture delivery device
ES2581774T3 (es) * 2008-08-29 2016-09-07 Janssen Biotech, Inc. Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes
EP2690175B1 (de) 2008-09-02 2016-12-28 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
JP5529142B2 (ja) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 血清アミロイドａ遺伝子の発現を阻害するための脂質製剤組成物および方法
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
DK3335728T3 (da) 2008-10-10 2020-02-24 Childrens Medical Center Biokemisk stabiliseret hiv-1 env-trimervaccine
SI2937418T1 (en) 2008-10-20 2018-02-28 Alnylam Pharmaceuticals, Inc. Compounds and procedures for inhibiting the expression of transthyretin
US20120052066A1 (en) 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
JP5855462B2 (ja) 2008-12-10 2016-02-09 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＮＡＱを標的としたｄｓＲＮＡ組成物および発現を阻害するための方法
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
KR20110100316A (ko) 2009-02-03 2011-09-09 에프. 호프만-라 로슈 아게 Ｐｔｐ1ｂ 유전자의 발현을 억제하기 위한 조성물 및 방법
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
JP5841044B2 (ja) 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 複合糖質ワクチン
US9675673B2 (en) * 2009-04-24 2017-06-13 Ingeneron Incorporated Transluminal delivery of oncoltyic viruses for cancer therapy
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
KR20120069610A (ko) * 2009-05-15 2012-06-28 에프. 호프만-라 로슈 아게 글루코코르티코이드 수용체(ｇｃｒ) 유전자의 발현을 억제하는 조성물 및 방법
WO2010141752A1 (en) 2009-06-03 2010-12-09 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
AR078921A1 (es) 2009-11-09 2011-12-14 Hoffmann La Roche Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US20110196016A1 (en) * 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
ES2893199T3 (es) 2010-03-29 2022-02-08 Alnylam Pharmaceuticals Inc Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
EP2377888A1 (de) 2010-04-07 2011-10-19 Corimmun GmbH Fusionsprotein
US11020444B2 (en) * 2010-04-23 2021-06-01 Scicotec Gmbh Transluminal delivery of viruses for treatment of diseased tissue
CA2796965C (en) 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Method for increasing permeability of an epithelial barrier
RU2585159C2 (ru) 2010-04-28 2016-05-27 Кимберли-Кларк Ворлдвайд, Инк. Устройство доставки лекарственного средства, применяемого при ревматоидном артрите
WO2011135532A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. Composite microneedle array including nanostructures thereon
CA2797205C (en) * 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of sirna
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
JP2013533243A (ja) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
PL2608802T3 (pl) 2010-08-27 2017-08-31 Pantarhei Bioscience B.V. Immunoterapeutyczny sposób leczenia raka gruczołu krokowego
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
US20120076736A1 (en) * 2010-09-17 2012-03-29 Rochester Institute Of Technology Host supported genetic biosensors
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
WO2012052258A1 (en) 2010-10-18 2012-04-26 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
PL2635299T3 (pl) 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
GB2485385A (en) 2010-11-12 2012-05-16 Univ Manchester Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP2698635A3 (de) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US11458290B2 (en) 2011-05-11 2022-10-04 Ekos Corporation Ultrasound system
US9592398B2 (en) 2011-05-12 2017-03-14 Medtronic, Inc. Leadless implantable medical device with osmotic pump
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
RU2631805C2 (ru) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
JP6165723B2 (ja) 2011-06-30 2017-07-19 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
US8969519B2 (en) 2011-09-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
EP2766028B1 (de) 2011-10-14 2017-08-16 F. Hoffmann-La Roche AG Peptidinhibitoren von bace1
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
SI3366775T1 (sl) 2011-11-18 2022-09-30 Alnylam Pharmaceuticals, Inc. Modificirana sredstva RNAI
NZ715957A (en) * 2012-02-07 2017-08-25 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013120553A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
DK2814842T3 (en) 2012-02-15 2018-12-10 Novo Nordisk As ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
EP3597254A1 (de) 2012-06-05 2020-01-22 Muffin Incorporated Zur zelltherapie nützliche kathetersysteme und -verfahren
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP2877214B1 (de) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Prognose von mit diabetes assoziierten komplikationen
EP3613765A1 (de) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antikörper gegen abstossungs führung molekül b (rgmb)
WO2014022739A2 (en) 2012-08-03 2014-02-06 Alnylam Pharmaceuticals, Inc. Modified rnai agents
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
EP2914278B1 (de) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 und cs1, pharmazeutische zusammensetzungen mit den peptiden und verfahren zur verwendung derartiger peptide sowie zusammensetzungen
US9340787B2 (en) 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
PT2968461T (pt) 2013-03-13 2022-12-26 Genzyme Corp Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
EP2992112B1 (de) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
AU2013388083B2 (en) 2013-05-01 2019-08-22 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
EP3293275B1 (de) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
US9982236B2 (en) 2013-06-13 2018-05-29 Orgenesis Ltd. Cell populations, methods of transdifferentiation and methods of use thereof
EP3027225B1 (de) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur modulierung der thermogenese mit transformierender wachstumsfaktor alpha
JP6297692B2 (ja) 2013-08-08 2018-03-20 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低侵襲処置用クランプデバイスおよびその使用
ES2647789T3 (es) 2013-08-08 2017-12-26 Global Bio Therapeutics, Inc. Dispositivo de inyección para procedimientos mínimamente invasivos
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015066190A1 (en) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Methods and compositions for inhibting oxidative stress
WO2015081290A1 (en) 2013-11-27 2015-06-04 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
WO2015191892A2 (en) 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EP3172232B1 (de) 2014-07-17 2023-12-27 Novo Nordisk A/S Ortsgerichtete mutagenese von trem-1 antikörpern zur reduktion der viskosität.
CN107075516A (zh) 2014-08-20 2017-08-18 阿尔尼拉姆医药品有限公司 经修饰的双链rna试剂
WO2016040488A2 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
ES2804826T3 (es) 2014-09-16 2021-02-09 Synermore Biologics Co Ltd Anticuerpo anti-EGFR y usos del mismo
US10092742B2 (en) 2014-09-22 2018-10-09 Ekos Corporation Catheter system
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CN113230384A (zh) 2014-10-09 2021-08-10 丹娜法伯癌症研究院 用于治疗免疫失调的多次-可变il-2剂量方案
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
EP3778644A3 (de) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusionsproteine und verfahren dafür
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
US20180036334A1 (en) 2015-02-13 2018-02-08 Icahn School Of Medicine At Mount Sinai Rna containing compositions and methods of their use
US10487324B2 (en) 2015-02-25 2019-11-26 Washington University Methods to detect motor neuron disease comprising micro-RNAs
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
CN107980062B (zh) 2015-04-03 2022-11-25 马萨诸塞大学 用于靶向亨廷汀mRNA的寡核苷酸化合物
PL3277815T3 (pl) 2015-04-03 2022-03-21 University Of Massachusetts Związki oligonukleotydowe do leczenia stanu przedrzucawkowego i innych zaburzeń angiogennych
US20180104289A1 (en) 2015-04-08 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Viral gene therapy as treatment for cholesterol storage disease or disorder
SG10201909209RA (en) 2015-05-05 2019-11-28 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
WO2016183585A1 (en) 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
US10656025B2 (en) 2015-06-10 2020-05-19 Ekos Corporation Ultrasound catheter
US11009509B2 (en) 2015-06-24 2021-05-18 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
EP3328376A4 (de) 2015-07-31 2019-03-13 The Johns Hopkins University Verfahren und zusammensetzung zur behandlung metabolischer umprogrammierungserkrankungen
BR112018002087A2 (pt) 2015-07-31 2018-09-18 Inst Of Organic Chemistry And Biochemistry As Cr V V I pró-fármacos de análogos de glutamina
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN108271387B (zh) 2015-08-07 2023-06-27 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3702470A3 (de) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduktion von er-mam-lokalisiertem app-c99 und verfahren zur behandlung von morbus alzheimer
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
US20210106661A1 (en) 2015-10-29 2021-04-15 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017123934A1 (en) 2016-01-13 2017-07-20 Merial, Inc. Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
JP2019503394A (ja) 2016-01-31 2019-02-07 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 分岐オリゴヌクレオチド
CN116920085A (zh) 2016-02-12 2023-10-24 詹森药业有限公司 抗-vista（b7h5）抗体
EP3433365B1 (de) 2016-03-21 2023-08-02 Dana-Farber Cancer Institute, Inc. T-zell-erschöpfungszustandsspezifische genexpressionsregulatoren und verwendungen davon
JP7184751B2 (ja) 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3496758A4 (de) 2016-08-12 2020-11-11 University of Massachusetts Konjugierte oligonukleotide
JP7466308B2 (ja) 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
EP3609577A4 (de) 2017-04-14 2021-03-24 University of Massachusetts Braune fettselektive adipokine
SG11201911256UA (en) 2017-05-08 2020-01-30 Orgenesis Ltd Transdifferentiated cell populations and methods of use thereof
EP3634496A4 (de) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
EP3642345A1 (de) 2017-06-20 2020-04-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Codon-optimierte humane npc1-gene zur behandlung von morbus niemann-pick typ c1 und verwandten erkrankungen
CA3061752A1 (en) 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of alpha-enac and methods of use
KR20200047660A (ko) 2017-09-01 2020-05-07 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드
EP3460057A1 (de) 2017-09-22 2019-03-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kdac varianten und deren nutzung
AU2018346681B2 (en) 2017-10-05 2024-02-22 Epivax, Inc. Regulatory T cell epitopes
EP3728281A1 (de) 2017-12-21 2020-10-28 Alnylam Pharmaceuticals Inc. Chiral angereicherte doppelsträngige rna-wirkstoffe
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2019229264A1 (en) 2018-06-01 2019-12-05 Sanofi Combination therapy for treating hepatitis b virus infection
US20220062378A1 (en) 2018-06-21 2022-03-03 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
US11827882B2 (en) 2018-08-10 2023-11-28 University Of Massachusetts Modified oligonucleotides targeting SNPs
EP3626820A1 (de) 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Krebsbekämpfende zusammensetzungen mit mirna-imitatoren und verwendungen davon
US20220056444A1 (en) 2018-12-05 2022-02-24 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
US11116778B2 (en) 2019-01-15 2021-09-14 Empirico Inc. Prodrugs of ALOX-15 inhibitors and methods of using the same
US20230057355A1 (en) 2019-02-13 2023-02-23 University Of Rochester Gene networks that mediate remyelination of the human brain
EP3941938A1 (de) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
US11629347B2 (en) 2019-05-06 2023-04-18 University Of Massachusetts Anti-C9ORF72 oligonucleotides and related methods
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
JP2023505168A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インターフェロン会合抗原結合タンパク質及びこれらの使用
CA3163356A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition
EP4182458A2 (de) 2020-07-20 2023-05-24 Dana-Farber Cancer Institute, Inc. Verfahren und zusammensetzungen zur behandlung und prävention von coronavirusinfektionen
EP4343004A2 (de) 2020-10-19 2024-03-27 Dana-Farber Cancer Institute, Inc. Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
AU2022218771A1 (en) 2021-02-11 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods of treating cancers using sting agonists
AU2022229805A1 (en) 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
IL309072A (en) 2021-06-09 2024-02-01 Evotec Int Gmbh Interferon-related antigen-binding proteins for use in the treatment or prevention of coronavirus infection
BR112023026862A2 (pt) 2021-06-23 2024-03-05 Beth Israel Deaconess Medical Ct Inc Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
WO2023280988A1 (en) 2021-07-09 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving relaxation of striated myocytes
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4332893A (en) * 1980-06-13 1982-06-01 Rosenberg Ralph A Process for the production of an insulin-producing cell line of pancreatic beta cells
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
DE3744785A1 (de) * 1987-12-11 1989-08-17 Theurer Karl Eugen Verwendung von ruecklaeufigen spiegelbildlichen anti-sense-nucleinsaeuren gegen krebserkrankungen
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0737750B1 (de) † 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
WO1990011734A1 (en) * 1989-03-31 1990-10-18 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US7331366B1 (en) 2005-05-31 2008-02-19 Patterson Brian A Money and card holding assembly

Also Published As

Publication number Publication date
JP2002239010A (ja) 2002-08-27
EP1213032B1 (de) 2008-02-13
DK0591385T3 (da) 2002-06-24
US5328470A (en) 1994-07-12
ATE385810T1 (de) 2008-03-15
EP1013287A2 (de) 2000-06-28
DE69232497D1 (de) 2002-04-25
EP0591385A1 (de) 1994-04-13
DE69232497T2 (de) 2002-11-14
EP1927368A2 (de) 2008-06-04
JPH06509328A (ja) 1994-10-20
JP3712409B2 (ja) 2005-11-02
EP1927368A3 (de) 2008-06-11
CA2112376A1 (en) 1993-01-07
ES2301602T3 (es) 2008-07-01
ATE214576T1 (de) 2002-04-15
EP0591385A4 (en) 1996-11-27
JP2001213806A (ja) 2001-08-07
EP1013287A3 (de) 2000-07-05
EP0591385B1 (de) 2002-03-20
EP1213032A1 (de) 2002-06-12
WO1993000051A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
ATE214576T1 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
Raper et al. Profound reversible myocardial depression after anaphylaxis
Banting The history of insulin
Waikakul et al. Prognostic factors for major limb re-implantation at both immediate and long-term follow-up
WO1996011021A3 (en) Treatment of tissues to reduce subsequent response to injury
DE69213744T2 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin-technologie
Palande et al. Surgical decompression of posterior tibial neurovascular complex in treatment of certain chronic plantar ulcers and posterior tibial neuritis in leprosy
DAVIS et al. Aloe vera and inflammation
Antoniades Hypoglycaemic effect of adipose-tissue extracts in adrenalectomised rats
Killip Coronary bypass surgery. Where we stand today.
O'Brien et al. A chronic conscious dog model for direct transhepatic studies in normal and pancreatic islet cell transplanted dogs
Charlesworth The role of minimally invasive surgery
RU1780741C (ru) Способ лечени деформирующего остеоартроза
Harris et al. Bundle Branch Block
Harris et al. Bundle Branch Block
Africa An Act (No. 65 of 1983) to provide for the donation or the making available of human bodies and tissue for the purposes of medical or dental training, research or therapy or the advancement of medicine or dentistry in general; for the post-mortem examination of certain human bodies; for the removal of tissue, blood and gametes from the bodies of living persons and the use thereof for medical or dental purposes; for the control of the artificial insemination of persons; and for the regulation of the import and export of human tissue, blood and gametes; and to provide for matters connected therewith. Date of commencement: 12 July 1985 (the Human Tissue Act, 1983)
Pandya Surgery on the peripheral nerves in leprosy
SOROKINA et al. Hydrocortisone and aldosterone content of the blood of patients undergoing magnetic field treatments for coronary heart disease
SU1174966A1 (ru) Способ моделировани осложненного инфаркта миокарда
Page AN EXTENSOR KNEE SPLINT.
Bogomilsky et al. The use of venous homotransplant in tympanoplasty
Troshev et al. Some clinical-morphological specificities in pinna burns
Cannon Symposium on Basic Science in Plastic Surgery
Suchet Chronic gonococcal arthritis treated with penicillin
Young The Position To-Day Of Tuberculin In Treatment